Ticker Details
Karyopharm Therapeutics Inc. Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.
IPO Date:	November 6, 2013
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$184.93M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.38 | 3.49%
Avg Daily Range (30 D):	$0.30 | 3.47%
Avg Daily Range (90 D):	$0.35 | 4.55%

Institutional Daily Volume
Avg Daily Volume:	.9M
Avg Daily Volume (30 D):	.43M
Avg Daily Volume (90 D):	.8M

Trade Size
Avg Trade Size (Sh.):	135
Avg Trade Size (Sh.) (30 D):	87
Avg Trade Size (Sh.) (90 D):	116

Institutional Trades
Total Institutional Trades:	2,369
Avg Institutional Trade:	$1.64M
Avg Institutional Trade (30 D):	$1.43M
Avg Institutional Trade (90 D):	$1.44M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.87M
Avg Closing Trade (30 D):	$.51M
Avg Closing Trade (90 D):	$.6M
Avg Closing Volume:	16.36K

News

Mar 1, 2025 @ 1:45 PM International Myeloma Foundation (IMF) Celebrates ... Source: International Myeloma Foundation

Nov 25, 2024 @ 4:00 PM Glioblastoma Multiforme Treatment Market Size to R... Source: Precedence Research

Sep 5, 2024 @ 6:16 PM Down -12.14% in 4 Weeks, Here's Why Karyopharm The... Source: Zacks

Jul 8, 2024 @ 5:02 PM Advanced Melanoma Clinical Trial Pipeline Analysis... Source: Delveinsight

May 8, 2024 @ 8:45 PM Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Ca... Source: newsfeedback@fool.com (Motley Fool Transcribing)

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-16.16	$-1.02	$-7
Diluted EPS	$-16.38	$-1.24	$-7
Revenue	$151.12M	$35.07M	$34.08M
Gross Profit
Net Income / Loss	$-194.97M	$-22.39M	$-102.2M
Operating Income / Loss	$-84.21M	$-26.76M	$-17.84M
Cost of Revenue
Net Cash Flow	$28.36M	$30.28M	$22.87M
PE Ratio

Splits
Feb 26, 2025	1:15